Millennium Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Millennium Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.02M	Buy	2,612,277 +1,116,438	+75%	+$4.31M	﹤0.01%	2400
2025 Q4	$6.12M	Buy	+1,495,839	New	+$7.41M	﹤0.01%	2787
2025 Q3	–	Sell	-739,408	Closed	-$3.74M	–	6406
2025 Q2	$3.74M	Buy	739,408 +237,300	+47%	+$1.17M	﹤0.01%	3277
2025 Q1	$2.66M	Buy	502,108 +473,798	+1,674%	+$3.45M	﹤0.01%	3507
2024 Q4	$191K	Sell	28,310 -10,473	-27%	-$70.4K	﹤0.01%	5324
2024 Q3	$256K	Buy	+38,783	New	+$278K	﹤0.01%	5302
2024 Q2	–	Sell	-11,077	Closed	-$96.6K	–	6448
2024 Q1	$110K	Buy	+11,077	New	+$123K	﹤0.01%	5552
2023 Q4	–	Sell	-658,355	Closed	-$5.04M	–	6470
2023 Q3	$5.04M	Buy	+658,355	New	+$6.57M	﹤0.01%	2673
2023 Q2	–	Sell	-646,610	Closed	-$4.31M	–	6612
2023 Q1	$4.31M	Sell	646,610 -48,763	-7%	-$387K	﹤0.01%	2740
2022 Q4	$5.36M	Buy	695,373 +455,977	+190%	+$4.47M	﹤0.01%	2753
2022 Q3	$2.55M	Sell	239,396 -143,778	-38%	-$1.46M	﹤0.01%	3527
2022 Q2	$3.12M	Sell	383,174 -111,978	-23%	-$749K	﹤0.01%	3254
2022 Q1	$3.54M	Buy	495,152 +461,323	+1,364%	+$4.9M	﹤0.01%	3315
2021 Q4	$579K	Buy	+33,829	New	+$637K	﹤0.01%	4925

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's RXRX Position: Q1 2026 in Review

Millennium Management increased its Recursion Pharmaceuticals (RXRX) stake by 75% in Q1 2026, buying an estimated $4.31M and bringing the position to 2,612,277 shares worth $8.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Millennium Management first reported a position in RXRX in Q4 2021 and has held it in 14 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Millennium Management held 2,612,277 shares of Recursion Pharmaceuticals worth $8.02M as of Q1 2026.
Millennium Management bought 1,116,438 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.31M.
Recursion Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2400 holding.
Millennium Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.